Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
Thu, 29/06/2017 - 07:30
Fri, 30/09/2016 - 10:12
ProAxsis Limited is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay.
Mon, 12/09/2016 - 11:15
London, UK, 12th September 2016 / Sciad Newswire / NALIA Systems is pleased to announce the filing of two new patent applications that highlight the co
Wed, 20/01/2016 - 13:00
BÜHLMANN Laboratories is proud to announce the availability of its products directly from its new North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire.